

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY DOCKET NO. 11068-052-999 (Formerly 65166/JPW)		APPLICATION NO 09/874,475	
				APPLICANT Petrooulos et al.			
				FILING DATE 6/04/01		GROUP 1648	
U.S. PATENT DOCUMENTS							
*EXAMINE R INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
W	A01	5,837,464	11/17/98	Capon et al.	—	—	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
W	A02	WO 97/27319	1/29/97	PCT	—	—	

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

W	A03	Alkhatib <i>et al.</i> , 1996, "CC CKR5: A Rantes, MIP-1alpha, MIP-1 Beta Receptor as a Fusion Cofactor for Macrophage-tropic Hiv-1," <i>Science</i> , 272:1955-58.
	A04	Allaway <i>et al.</i> , 1993, "Synergistic Inhibition of HIV-1 Envelope-Mediated Cell Fusion by CD4-based Molecules in Combination with Antibodies to Gp120 or Gp41," <i>Aids Res. Hum. Retroviruses</i> , 9:581-87.
	A05	Baba <i>et al.</i> , 1999, "A Small-molecule, Nonpeptide CCR5 Antagonist with Highly Potent and Selective Anti-hiv-1 Activity," <i>Proc. Natl. Acad. Sci. USA</i> , 96:5698-03.
	A06	Barnes, W.M., 1994, "PCR amplification of up to 35-kb DNA with high fidelity and high yield from lambda bacteriophage templates," <i>Proc. Natl. Acad. Sci. USA</i> 91, 2216-20.
	A07	Baxter <i>et al.</i> , 1999, "A Pilot Study of the Short-term Effects of Antiretroviral Management Based on Plasma Genotypic Antiretroviral Resistance Testing (Gart) in Patients Failing Antiretroviral Therapy," <u>Presented at the 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.</u>
	A08	Bernard and Couturier, 1992, "Cell Killing by the F Plasmid CcdB protein Involves Poisoning of DNATopoisomerase II Complexes," <i>J. Mol. Bio.</i> 226:735-45.
	A09	Bernard <i>et al.</i> , 1993, "The F Plasmid CcdB protein Induces Efficient ATP-dependent Dna Cleavage by Gyrase," <i>J. Mol. Biol.</i> 23:534-41.
	A10	Bleul <i>et al.</i> , 1996, "The Lymphocyte Chemoattractant Sdf-1 Is a Ligand for Lestr/fusin and Blocks Hiv-1 Entry," <i>Nature</i> 382:829-33.
	A11	Bridger <i>et al.</i> , 1999, "Synthesis and Structure-activity Relationships of Phenylenebis(methylene)-linked Bis-azamacrocycles That Inhibit HIV-1 and HIV-2 Replication by Antagonism of the Chemokine Receptor CXCR4," <i>J. Med. Chem.</i> 42:3971-81.
	A12	Coffin, 1995, "HIV Population Dynamics in Vivo: Implications for Genetic Variation, Pathogenesis, and Therapy," <i>Science</i> 267:483-489.
	A13	DHHS (Department of Health and Human Services), 2000, Henry Kaiser Family Foundation: "Guidelines for the Use of Antiretrovirals Agents in HIV-infected Adults and Adolescents."
	A14	Dorn <i>et al.</i> , 2001, "Antagonists of the Human CCR5 Receptor as Anti-HIV-1 Agents. Part 1: Discovery and Initial Structure-Activity Relationships for 1-Amino-2-phenyl-4-(piperidin-1-yl) butanes," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:259-64.
	A15	Finke <i>et al.</i> , 2001, "Antagonists of the Human CCR5 Receptor as Anti-HIV-1 Agents. Part 4: Synthesis and Structure-Activity Relationships for 1-[N-(Methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-(4-(N-(alkyl)-N-(benzyloxycarbonyl)amino)piperidin-1-yl) butanes," <i>Bioorganic & Medicinal Chemistry Letters</i> 11:2475-79.
	A16	Gerdes <i>et al.</i> , 1990, "The Hok Killer Gene Family in Gram-negative Bacteria," <i>The New Biologist</i> : 2:946-56.
	A17	Hertogs <i>et al.</i> , 1998, "A Rapid Method for Simultaneous Detection of Phenotypic Resistance to Inhibitors of protease and Reverse Transcriptase in Recombinant Human Immunodeficiency Virus Type 1 Isolates from Patients Treated with Antiretroviral Drugs," <i>Antimicrob. Agents Chemother.</i> 42:269-76.
	A18	Hwang <i>et al.</i> , 1997, "A Conditional Self-inactivating Retrovirus Vector That Uses a Tetracycline-responsive Expression System," <i>J. Virol.</i> 71: 7128-31.
	A19	Japour <i>et al.</i> , 1993, "Standardized Peripheral Blood Mononuclear Cell Culture Assay for Determination of Drug Susceptibilities of Clinical Human Immunodeficiency Virus Type 1 Isolates," <i>Antimicrob. Agents Chemother.</i>

		37:1095-01.
AW	A20	Judice <i>et al.</i> , 1997, "Inhibition HIV Type 1 Infectivity by Constrained Alpha-helical Peptides: Implications for the Viral Fusion Mechanism," <i>Proc. Natl. Acad. Sci. USA</i> 94:13426-30.
	A21	Kilby <i>et al.</i> , 1998, "Potent Suppression of HIV-1 Replication in Humans by T-20, a Peptide Inhibitor of Gp41-mediated Virus Entry," <i>Nat Med.</i> 4:1302-07.
	A22	Mascola <i>et al.</i> , 2000, "HIV-1 Entry at the Mucosal Surface: Role of Antibodies in Protection," <i>AIDS</i> , 14 (suppl 3): S167-174.
	A23	Mascola <i>et al.</i> , 2000, "Protection of Macaques Against Vaginal Transmission of a Pathogenic HIV-1/siv Chimeric Virus by Passive Infusion of Neutralizing Antibodies," <i>Nature Med.</i> 6:207-10.
	A24	Miyoshi <i>et al.</i> , 1998, "Development of a Self-inactivating Lentivirus Vector," <i>J. Virol.</i> 72:8150-57.
	A25	Naviaux <i>et al.</i> , 1996, "The Pcl Vector System: Rapid production of Helper-free, High-titer, Recombinant Retroviruses," <i>J. Virol.</i> 70: 5701-05.
	A26	Petropoulos <i>et al.</i> , 2000, "A Novel Phenotypic Drug Susceptibility Assay for HIV-1," <i>Antimicrob. Agents & Chem.</i> 44:920-28.
	A27	Piketty <i>et al.</i> , 1999, "Efficacy of a Five-drug Combination Including Ritonavir, Saquinavir and Efavirenz in Patients Who Failed on a Conventional Triple-drug Regimen: Phenotypic Resistance to protease Inhibitors predicts Outcome of Therapy," <i>Aids</i> : 13:f71-f77.
	A28	Porter <i>et al.</i> , 1998, "Cationic Liposomes Enhance the Rate of Transduction by a Recombinant Retroviral Vector in Vitro and in Vivo," <i>J. Virol.</i> 72:4832-40.
	A29	Reimann <i>et al.</i> , 1995, "In Vivo Administration of CD4-specific Monoclonal Antibody: Effect on provirus Load in Rhesus Monkeys Chronically Infected with the Simian Immunodeficiency Virus of Macaques," <i>Aids Res. Hum. Retroviruses</i> 11:517-25.
	A30	Rimsky <i>et al.</i> , 1998, "Determinants of Human Immunodeficiency Virus Type 1 Resistance to Gp41-derived Inhibitory Peptides," <i>J. Virol.</i> 72:986-93.
	A31	Rodriguez-Rosado <i>et al.</i> , 1999, "Introduction of HIV Drug-resistance Testing in Clinical Practice," <i>Aids</i> 13:1007-14.
	A32	Sarkar <i>et al.</i> , 1990, "The "Megaprimer" Method of Site-Directed Mutagenesis," <i>Biotechniques</i> 8:404-07.
	A33	Sarkat <i>et al.</i> , 1990, "Shedding Light on PCR contamination," <i>Nature</i> 343:27.
	A34	Schinazi <i>et al.</i> , 1999, "Mutations in Retroviral Genes Associated with Drug Resistance," <i>Intl. Antiviral News</i> : 7:46-49.
	A35	Shi <i>et al.</i> , 1997, "A Recombinant Retroviral System for Rapid In Vivo Analysis of Human Immunodeficiency Virus Type 1 Susceptibility to Reverse Transcriptase Inhibitors," <i>Antimicrobial Agents and Chemotherapy</i> , 41:2781-85
	A36	Wild <i>et al.</i> , 1992, "A Synthetic Peptide Inhibitor of HIV Replication: Correlation Between Solution Structure and Viral Inhibition," <i>Proc. Natl. Acad. Sci. USA</i> 89:10537-41.
	A37	http://hiv-web.lanl.gov/content/index Last accessed on May 1, 2003.
	A38	Zennou <i>et al.</i> , 1998, "Loss of Viral Fitness Associated with Multiple Gag and Gag-pol processing Defects in Human Immunodeficiency Virus Type 1 Variants Selected for Resistance to Protease Inhibitors in vivo," <i>J. Virol.</i> 72:3300-06.
↓	A39	Ziermann <i>et al.</i> , 2000, "A Mutation in HIV-1 Protease, N88s, That Causes in Vitro Hypersensitivity to Amprenavir," <i>J. Virol.</i> 74:4414-19.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.